NICE recommends drug to prevent episodes of hepatic encephalopathy

Rifaximin (Targaxan) has been accepted by NICE for preventing recurrent hepatic encephalopathy.

Hepatic encephalopathy is a complication of cirrhosis. | SCIENCE PHOTO LIBRARY
Hepatic encephalopathy is a complication of cirrhosis. | SCIENCE PHOTO LIBRARY

Rifaximin is recommended by NICE as an option for reducing recurrent episodes of overt hepatic encephalopathy in adults.

Further information
NICE technology appraisal TA337

Rifaximin is a semi-synthetic derivative of the antibiotic rifamycin. It is thought to delay episodes of hepatic encephalopathy by reducing intestinal absorption and production of ammonia. High levels of ammonia and other toxins are believed to cause the neurocognitive symptoms of hepatic encephalopathy.

The SPC notes that over 90% of patients in the pivotal study of rifaximin were also taking lactulose.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

'Innovative' heart failure treatment recommended by NICE

'Innovative' heart failure treatment recommended by NICE

Dapagliflozin (Forxiga), the first SGLT2 inhibitor...

Drug price changes - live tracker

Drug price changes - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

Pregabalin linked to severe respiratory depression in absence of opioids

Pregabalin linked to severe respiratory depression in absence of opioids

The MHRA advises prescribers to consider adjustment...